Cargando…

Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival

SIMPLE SUMMARY: Immunotherapy is the standard of care in patients harboring metastasized melanoma. However, once further tumor growth is stopped it remains unclear when immunotherapy can be safely ceased. This clinical question is increasingly raised especially in patients with a strong desire to di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schank, Timo E., Forschner, Andrea, Sachse, Michael Max, Dimitrakopoulou-Strauss, Antonia, Sachpekidis, Christos, Stenzinger, Albrecht, Volckmar, Anna-Lena, Enk, Alexander, Hassel, Jessica C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198795/ https://www.ncbi.nlm.nih.gov/pubmed/34073477 http://dx.doi.org/10.3390/cancers13112616

Ejemplares similares

Assessment of early metabolic progression in melanoma patients under immunotherapy: an (18)F-FDG PET/CT study
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Quantitative Dynamic (18)F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Quantitative, Dynamic (18)F-FDG PET/CT in Monitoring of Smoldering Myeloma: A Case Report
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Application of the long axial field-of-view PET/CT with low-dose [(18)F]FDG in melanoma
por: Sachpekidis, Christos, et al.
Publicado: (2022)

The prognostic value of [(18)F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria
por: Sachpekidis, Christos, et al.
Publicado: (2023)

Interim [(18)F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
por: Sachpekidis, Christos, et al.
Publicado: (2020)

Can physiologic colonic [(18)F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?
por: Sachpekidis, Christos, et al.
Publicado: (2023)

Functional Imaging with (18)F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient
por: Sachpekidis, Christos, et al.
Publicado: (2017)

Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
por: Sachpekidis, Christos, et al.
Publicado: (2019)

Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review
por: Dimitrakopoulou-Strauss, Antonia, et al.
Publicado: (2017)

Long axial field of view (LAFOV) PET-CT: implementation in static and dynamic oncological studies
por: Dimitrakopoulou-Strauss, Antonia, et al.
Publicado: (2023)

Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives
por: Dimitrakopoulou-Strauss, Antonia, et al.
Publicado: (2020)

Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab
por: Breki, Christina-Marina, et al.
Publicado: (2016)

Fractal and Multifractal Analysis of PET-CT Images for Therapy Assessment of Metastatic Melanoma Patients under PD-1 Inhibitors: A Feasibility Study
por: Kosmou, Anastasia, et al.
Publicado: (2021)

Positron Emission Tomography in Merkel Cell Carcinoma
por: Sachpekidis, Christos, et al.
Publicado: (2020)

PET Diagnostic Molecules Utilizing Multimeric Cyclic RGD Peptide Analogs for Imaging Integrin α(v)β(3) Receptors
por: Liolios, Christos, et al.
Publicado: (2021)

The prognostic significance of [(18)F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients
por: Dimitrakopoulou-Strauss, Antonia, et al.
Publicado: (2012)

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018)

Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic (18)F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group
por: Sachpekidis, Christos, et al.
Publicado: (2019)

Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined (18)F-FDG and (18)F-FLT PET/CT imaging
por: Sachpekidis, C., et al.
Publicado: (2018)

Application of an artificial intelligence-based tool in [(18)F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma
por: Sachpekidis, Christos, et al.
Publicado: (2023)

Can (18)F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?
por: Sachpekidis, Christos, et al.
Publicado: (2020)

Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
por: Machiraju, Devayani, et al.
Publicado: (2021)

Imaging Features of Multiple Myeloma Extramedullary Lesions in the Liver with 18F-FDG PET/CT, Contrast-Enhanced CT and MRI
por: Papamichail, Dimitris, et al.
Publicado: (2019)

Characterization of multiple myeloma osseous lesions and diffuse infiltration pattern by 18F-FDG-PET/CT, static MRI and diffusion-weighted MR Imaging (DWI-MRI): a comparative multimodality imaging study
por: Mosebach, J, et al.
Publicado: (2014)

Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
por: Ferdinandus, Justin, et al.
Publicado: (2022)

Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib
por: Kasper, Bernd, et al.
Publicado: (2013)

Immuno-Imaging (PET/SPECT)–Quo Vadis?
por: Kramer, Carsten S., et al.
Publicado: (2022)

Basic and clinical immunology – 3032. 18FDG-PET/CT findings (SUV-MAX) are correlated with survival in stage-4 squamous cell carcinoma
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Comparison of functional imaging in multiple myeloma patients: Indication for hybrid-imaging with PET/MRI?
por: Mosebach, J, et al.
Publicado: (2015)

Basic and clinical immunology – 3031. The correlation between serum protemics patterns of sTRAIL and CXCL8 with FDG-PET/CT findings in bevacizumab treated colon cancers
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [(18)F]-FDG PET/CT
por: Alberts, Ian, et al.
Publicado: (2021)

Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients
por: Salzmann, Martin, et al.
Publicado: (2020)

Hybrid imaging with [(68)Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer
por: Glemser, P. A., et al.
Publicado: (2022)

Quantitative techniques in (18)FDG PET scanning in oncology
por: Castell, F, et al.
Publicado: (2008)

Immunotherapies for the Treatment of Uveal Melanoma—History and Future
por: Schank, Timo E., et al.
Publicado: (2019)

Benign Colonic (18)F-FDG Uptake on Whole-Body FDG-PET Scan
por: Jang, Byung Ik
Publicado: (2012)

Incidental SARS-CoV-2-related findings in asymptomatic patients in [(18)F]-FDG-PET/CT—potential insights
por: Alberts, Ian, et al.
Publicado: (2020)

Detection of a primary tumor in the area of the renal artery with (18)F-FDG PET/CT in a patient with metastatic undifferentiated sarcoma and a history of mid-aortic syndrome: A case report
por: Sachpekidis, Christos, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_84cse41fh8vmo95j3a1oisbded